Thermo Fisher Scientific Inc., a global leader in scientific services, recently announced its participation in CPHI Frankfurt 2025, taking place from October 28 to 30. The company will present innovative solutions aimed at enhancing efficiency and scalability in biopharmaceutical manufacturing throughout the drug development process at booth #5.1A8 in Hall 5.1.
During the event, leaders from Thermo Fisher will engage in panel discussions addressing current industry trends, sustainable practices, and the importance of collaboration in speeding up the delivery of critical medicines. “Our aim is to refine the processes of drug discovery, development, and manufacturing to assist our clients in delivering high-quality treatments efficiently and safely,” stated Michael Shafer, executive vice president and president of biopharma services at Thermo Fisher.
Over the past year, Thermo Fisher has capitalized on its extensive offerings to reinforce its position as a partner in the biopharmaceutical landscape. This includes the introduction of the Accelerator Drug Development program, which has successfully collaborated on 700 projects across 14 therapeutic areas, particularly in oncology and neurology. The program provides biopharma clients with the necessary agility and predictability to navigate the complexities of drug development.
As part of the Accelerator initiative, Thermo Fisher is unveiling OSDPredict, a digital toolbox that utilizes artificial intelligence and machine learning to predict formulation behaviors and tackle significant challenges in small-molecule development. OSDPredict aims to offer data-driven insights that can save crucial active pharmaceutical ingredients, reduce timelines, and enhance the understanding of molecular behaviors.
Strategic Collaboration with OpenAI
In a significant move to advance drug development, Thermo Fisher has partnered with OpenAI to harness AI capabilities that streamline clinical research processes. This collaboration is expected to reduce the cycle time of clinical trials, thereby delivering increased value to the industry. Recently, Thermo Fisher also launched the Gibco Efficient-Pro Medium (+) Insulin, aimed at improving productivity in insulin-dependent CHO cell lines.
Further innovations include the introduction of the 5-liter DynaDrive Single-Use Bioreactor, which allows seamless scalability from one to 5,000 liters, enhancing the bioprocessing capabilities of the company. Additionally, the award-winning SteriSEQ Rapid Sterility Testing Kit promises reliable results in under a day, utilizing quantitative polymerase chain reaction technology to expedite the cell therapy manufacturing process.
Expansion of Clinical Development Capabilities
To strengthen its supply chain and meet the increasing demands of pharma and biotech sectors, Thermo Fisher is actively expanding its manufacturing capabilities through strategic acquisitions. This year, the company acquired a state-of-the-art sterile fill-finish and packaging facility in Ridgefield, New Jersey, from Sanofi, continuing to produce a diverse range of therapies at that location.
Moreover, Thermo Fisher has enhanced its bioprocessing offerings by incorporating advanced filtration technologies through the acquisition of Solventum”s Purification and Filtration business. The company has also expanded its sterile-fill finish capabilities with the addition of new filling lines in Plainville, Massachusetts, to support the commercialization of various therapies.
As part of its commitment to innovation, Thermo Fisher has engaged in a new research collaboration with the AstraZeneca BioVentureHub in Gothenburg, Sweden, and introduced the Clinical Trial Carbon Calculator, an open-access tool designed to assist biopharmaceutical companies in assessing and minimizing the environmental impact of clinical trials.
For more information on Thermo Fisher Scientific, visit thermofisher.com.
